Open access · CC-BY
via OpenAlex
A combination of metformin and galantamine exhibits synergistic benefits in the treatment of sarcopenia
Caterina Tezze, Francesco Ivan Amendolagine, Leonardo Nogara, Martina Baraldo, Stefano Ciciliot, Diletta Arcidiacono, Alice Zaramella, Giulio Masiero, Giulia Ferrarese, Stefano Realdon, Bert Blaauw, Giel Detienne, Ann T.J. Beliën, Marco Sandri, Evi M. Mercken
JCI Insight · 2023 · ▲ 36 citations
Mitochondrial dysfunction
Chronic inflammation
Disabled macroautophagy
Metformin
Human
Mouse
Preclinical / animal
Abstract
Age-associated sarcopenia, characterized by a progressive loss in muscle mass and strength, is the largest cause of frailty and disability in the elderly worldwide. Current treatments involve nonpharmacological guidelines that few subjects can abide by, highlighting the need for effective drugs. Preclinical models were employed to test the benefits of RJx-01, a combination drug composed of metformin and galantamine, on sarcopenia. In worms, RJx-01 treatment improved lifespan, locomotion, pharyngeal pumping, and muscle fiber organization. The synergistic effects of RJx-01 were recapitulated in a transgenic mouse model that displays an exacerbated aging phenotype (Opa1-/-). In these mice, RJx-01 ameliorated physical performance, muscle mass and force, neuromuscular junction stability, and systemic inflammation. RJx-01 also improved physical performance and muscle strength in 22-month-old WT mice and also improved skeletal muscle ultrastructure, mitochondrial morphology, autophagy(definition), lysosomal function, and satellite cell content. Denervation and myofiber damage were decreased in RJx-01-treated animals compared with controls. RJx-01 improved muscle quality rather than quantity, indicating that the improvement in quality underlies the beneficial effects of the combination drug. The studies herein indicate synergistic beneficial effects of RJx-01 in the treatment of sarcopenia and support the pursuit of RJx-01 in a human clinical trial as a therapeutic intervention for sarcopenia.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1172/jci.insight.168787
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Tezze, C., Amendolagine, F.I., Nogara, L., Baraldo, M., Ciciliot, S., Arcidiacono, D., Zaramella, A., Masiero, G., Ferrarese, G., Realdon, S., Blaauw, B., Detienne, G., Beliën, A.T., Sandri, M., & Mercken, E.M. (2023). A combination of metformin and galantamine exhibits synergistic benefits in the treatment of sarcopenia. <em>JCI Insight</em>. https://doi.org/10.1172/jci.insight.168787
Vancouver
Tezze C, Amendolagine FI, Nogara L, Baraldo M, Ciciliot S, Arcidiacono D, et al. A combination of metformin and galantamine exhibits synergistic benefits in the treatment of sarcopenia. JCI Insight. 2023. doi:10.1172/jci.insight.168787.
BibTeX
@article{caterina2023Acombi,
title = {A combination of metformin and galantamine exhibits synergistic benefits in the treatment of sarcopenia},
author = {Caterina Tezze and Francesco Ivan Amendolagine and Leonardo Nogara and Martina Baraldo and Stefano Ciciliot and Diletta Arcidiacono and Alice Zaramella and Giulio Masiero and Giulia Ferrarese and Stefano Realdon and Bert Blaauw and Giel Detienne and Ann T.J. Beliën and Marco Sandri and Evi M. Mercken},
journal = {JCI Insight},
year = {2023},
doi = {10.1172/jci.insight.168787},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The American Journal of Medicine 2006
Citation only
Inflammatory Markers and Loss of Muscle Mass (Sarcopenia) and Strength
Cell Death and Disease 2023
Open access · CC-BY
Clinical-grade human umbilical cord-derived mesenchymal stem cells improved skeletal muscle dysfunction in age-associated sarcopenia mice
Journal of the American Medical Directors Association 2014
Citation only
An Anthropometric Prediction Equation for Appendicular Skeletal Muscle Mass in Combination With a Measure of Muscle Function to Screen for Sarcopenia in Primary and Aged Care
International Journal of Molecular Sciences 2021
Open access · CC-BY
Mitochondrial Dynamics and Mitophagy in Skeletal Muscle Health and Aging
Sohag University 2026
Open access · US-GOV
Serum Insulin-like Growth Factor-1 to Albumin Ratio as a Biomarker for Sarcopenia Severity in End-Stage Renal Disease Patients on Hemodialysis
Zenodo (CERN European Organization for Nuclear Research) 2026
Preprint · OA